Real-world treatment characteristics for first-line therapy (1L) of advanced hepatocellular carcinoma (HCC) in Canada and Europe.

被引：0

作者：

Gill, Sharlene

Jaffe, Dena H.

DeCongelio, Marc

DuBell, Arnold N.

Shi, Jing

Wisniewski, Tami

Thompson, Gwilym

机构：

[1] BC Canc, Vancouver, BC, Canada

[2] Kantar Hlth, Tel Aviv, Israel

[3] Kantar Hlth, Horsham, PA USA

[4] Bristol Myers Squibb, Princeton, NJ USA

[5] Bristol Meyers Squibb, Uxbridge, Middx, England

来源：

关键词：

D O I：

10.1200/JCO.2019.37.4_suppl.353

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

353

引用

页数：2